Clinical Trial Update: Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated satralizumab as monotherapy for neuromyelitis optica and NMOSD, with completed status and results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuromyelitis Optica
• Neuromyelitis Optica Spectrum Disorder

Drugs mentioned

• Satralizumab (satralizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Neuromyelitis Optica (NMO), NMO Spectrum Disorder (NMOSD) | Phase 3 | Status: COMPLETED | Results posted: 2020-12-31